Outlook Therapeutics wins FDA approval for LYTENAVA in wet AMD
OTLK•Launch plans and sales target
The company said a U.S. launch is planned before the end of 2026, targeting conversion of off-label bevacizumab use in the retina market.
Outlook Therapeutics also flagged a path to more than $500 million in annual U.S. sales by 2030.
FDA approval for LYTENAVA in wet AMD
Outlook Therapeutics secured FDA approval for LYTENAVA, an ophthalmic bevacizumab formulation to treat wet age-related macular degeneration.
